Literature DB >> 20639220

Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.

Adeleke M Badejo1, Vaughn E Nossaman, Edward A Pankey, Manish Bhartiya, Chandrika B Kannadka, Subramanyam N Murthy, Bobby D Nossaman, Philip J Kadowitz.   

Abstract

BAY 41-8543 is a nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). Responses to intravenous injections of BAY 41-8543 were investigated under baseline and elevated tone conditions and when NO synthase (NOS) was inhibited with N(ω)-nitro-L-arginine methyl ester (L-NAME). Under baseline conditions, intravenous injections of BAY 41-8543 caused small decreases in pulmonary arterial pressure, larger decreases in systemic arterial pressure, and increases in cardiac output. When pulmonary arterial pressure was increased to ∼30 mmHg with an intravenous infusion of U-46619, intravenous injections of BAY 41-8543 produced larger dose-dependent decreases in pulmonary arterial pressure, and the relative decreases in pulmonary and systemic arterial pressure in response to the sGC stimulator were similar. Treatment with L-NAME markedly decreased responses to BAY 41-8543 when pulmonary arterial pressure was increased to similar values (∼30 mmHg) in U-46619-infused and in U-46619-infused plus L-NAME-treated animals. The intravenous injection of a small dose of sodium nitroprusside (SNP) when combined with BAY 41-8543 enhanced pulmonary and systemic vasodilator responses to the sGC stimulator in L-NAME-treated animals. The present results indicate that BAY 41-8543 has similar vasodilator activity in the systemic and pulmonary vascular beds when pulmonary vasoconstrictor tone is increased with U-46619. These results demonstrate that pulmonary and systemic vasodilator responses to BAY 41-8543 are significantly attenuated when NOS is inhibited by L-NAME and show that vasodilator responses to BAY 41-8543 are enhanced when combined with a small dose of SNP in L-NAME-treated animals. The present results are consistent with the concept that pulmonary and systemic vasodilator responses to the sGC stimulator are NO-independent; however, the vasodilator activity of the compound is greatly diminished when endogenous NO production is inhibited with L-NAME. These data show that BAY 41-8543 has similar vasodilator activity in the pulmonary and systemic vascular beds in the rat.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20639220      PMCID: PMC2957355          DOI: 10.1152/ajpheart.01101.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  38 in total

1.  NO-independent stimulators of soluble guanylate cyclase.

Authors:  A Straub; J P Stasch; C Alonso-Alija; J Benet-Buchholz; B Ducke; A Feurer; C Fürstner
Journal:  Bioorg Med Chem Lett       Date:  2001-03-26       Impact factor: 2.823

2.  NO-independent regulatory site on soluble guanylate cyclase.

Authors:  J P Stasch; E M Becker; C Alonso-Alija; H Apeler; K Dembowsky; A Feurer; R Gerzer; T Minuth; E Perzborn; U Pleiss; H Schröder; W Schroeder; E Stahl; W Steinke; A Straub; M Schramm
Journal:  Nature       Date:  2001-03-08       Impact factor: 49.962

3.  Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase.

Authors:  Alexander Straub; Jordi Benet-Buckholz; Rita Fröde; Armin Kern; Christian Kohlsdorfer; Peter Schmitt; Thomas Schwarz; Hans Martin Siefert; Johannes Peter Stasch
Journal:  Bioorg Med Chem       Date:  2002-06       Impact factor: 3.641

Review 4.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

5.  Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.

Authors:  Cristiane F Freitas; Rafael P Morganti; Joyce M Annichino-Bizzacchi; Gilberto De Nucci; Edson Antunes
Journal:  Clin Exp Pharmacol Physiol       Date:  2007 Jan-Feb       Impact factor: 2.557

6.  Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat.

Authors:  David B Casey; Adeleke M Badejo; Jasdeep S Dhaliwal; Subramanyam N Murthy; Albert L Hyman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

7.  Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies.

Authors:  Johannes-Peter Stasch; Cristina Alonso-Alija; Heiner Apeler; Klaus Dembowsky; Achim Feurer; Torsten Minuth; Elisabeth Perzborn; Matthias Schramm; Alexander Straub
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 8.  NO-independent, haem-dependent soluble guanylate cyclase stimulators.

Authors:  Johannes-Peter Stasch; Adrian J Hobbs
Journal:  Handb Exp Pharmacol       Date:  2009

9.  Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.

Authors:  Joachim Mittendorf; Stefan Weigand; Cristina Alonso-Alija; Erwin Bischoff; Achim Feurer; Michael Gerisch; Armin Kern; Andreas Knorr; Dieter Lang; Klaus Muenter; Martin Radtke; Hartmut Schirok; Karl-Heinz Schlemmer; Elke Stahl; Alexander Straub; Frank Wunder; Johannes-Peter Stasch
Journal:  ChemMedChem       Date:  2009-05       Impact factor: 3.466

10.  NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.

Authors:  Johannes-Peter Stasch; Peter Schmidt; Cristina Alonso-Alija; Heiner Apeler; Klaus Dembowsky; Michael Haerter; Markus Heil; Torsten Minuth; Elisabeth Perzborn; Ulrich Pleiss; Matthias Schramm; Werner Schroeder; Henning Schröder; Elke Stahl; Wolfram Steinke; Frank Wunder
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more
  16 in total

Review 1.  Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.

Authors:  George F Lasker; Jason H Maley; Edward A Pankey; Philip J Kadowitz
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

3.  Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action.

Authors:  A S Leitão Junior; R M Campos; J B G Cerqueira; M C Fonteles; C F Santos; G de Nucci; E H S Sousa; L G F Lopes; L F Gonzaga-Silva; N R F Nascimento
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

Review 4.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

5.  Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.

Authors:  Robrecht Thoonen; Patrick Y Sips; Kenneth D Bloch; Emmanuel S Buys
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

6.  Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm.

Authors:  Ludovic Waeckel; Cécile Badier-Commander; Thibaut Damery; Ralf Köhler; Patricia Sansilvestri-Morel; Serge Simonet; Christine Vayssettes-Courchay; Heike Wulff; Michel Félétou
Journal:  Pflugers Arch       Date:  2014-11-12       Impact factor: 3.657

7.  Analysis of responses to glyceryl trinitrate and sodium nitrite in the intact chest rat.

Authors:  Bobby D Nossaman; Edward A Pankey; Adeleke R Badejo; David B Casey; Satvika Uppu; Subramanyam N Murthy; Philip J Kadowitz
Journal:  Nitric Oxide       Date:  2012-03-29       Impact factor: 4.427

8.  Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.

Authors:  Edward A Pankey; Manish Bhartiya; Adeleke M Badejo; Umair Haider; Johannes-Peter Stasch; Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

9.  The sGC activator BAY 60-2770 has potent erectile activity in the rat.

Authors:  George F Lasker; Edward A Pankey; Terrence J Frink; Jonathan R Zeitzer; Korey A Walter; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

10.  Stimulators of soluble guanylyl cyclase: future clinical indications.

Authors:  Bobby D Nossaman; Philip J Kadowitz
Journal:  Ochsner J       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.